Inhibitors of bacterial IMPDH

A method of inhibiting bacterial IMPDH to decrease bacterial quantity in a patient, comprising administering to said patient a therapeutically effective amount of a compound of formula I:

• or a pharmaceutically acceptable salt thereof, wherein:
• Ring A is a 5-6 membered heteroaryl ring or a 4-7 membered saturated or partially unsaturated heterocyclic ring each ring having 1-4 heteroatoms independently selected from N, NR3, O, S, SO, or SO2;
• wherein said 5-6 membered heteroaryl ring system is optionally linearly fused to a second 5-6 membered aryl or heteroaryl ring or optionally linearly fused to a 4-7 membered saturated or partially unsaturated heterocyclic or carbocyclic ring;
• wherein said 5-6 membered aryl or heteroaryl fused ring contains 0-3 heteroatoms independently selected from N, O, or S;
• wherein said 4-7 membered fused ring contains 0-3 heteroatoms independently selected from N, NR3, O, S, SO, or SO2;
• wherein said 4-7 membered saturated or partially unsaturated heterocyclic ring is optionally linearly fused to a second 5-6 membered aryl or heteroaryl ring or optionally spirocyclic bound to a 4-7 membered saturated or partially unsaturated heterocyclic or carbocyclic ring;
• wherein said 5-6 membered aryl or heteroaryl fused ring contains 0-3 heteroatoms independently selected from N, O, or S;
• wherein said 4-7 membered spirocyclic ring contains 0-3 heteroatoms independently selected from N, NR3, O, S, SO, or SO2;
• and
• wherein any of said rings is optionally substituted with up to 2 substituents independently selected from J;
• J is —(C1-C4)-straight or branched alkyl chain, —(C2-C4)-straight or branched alkenyl or alkynyl, halogen, -(T)y—Ar, -(T)y—R′, —CF3, —OCF3, oxo, —C(O)R′, —C(O)C(O)R′, —CO2R′, —OR′, —N(R′)2, —SR′, —NO2, —CN, —C(O)N(R′)2, —OC(O)N(R′)2, —NR′C(O)R′, —NR′C(O)N(R′)2, —N(OR′)R′, —C(═NOR′)R′, —SO2R′, —SO2N(R′)2, —NR′SO2R′, —P(O)R′)2, —P(O)(OR′)2, or —OP(O)(OR′)2;
• wherein
• y is 0 or 1;
• T is a (C1-C4)-straight or branched alkyl chain, wherein one methylene unit of T is optionally replaced by —O—, —C(O)—, —NH—, or —S—;
• each R′ is independently selected from hydrogen, a (C1-C4)-straight or branched alkyl chain, or a 5-6 membered saturated, unsaturated, or aryl ring having 0-3 heteroatoms independently selected from N, O, or S;
• or
• two R′ groups together with the nitrogen to which they are bound optionally form a 3-6 membered heterocyclic ring;
• and
• each R′ is substituted with 0-3 groups independently selected from halogen, oxo, R0, N(R0)2, OR0, CO2R0, NR0C(O)R0, C(O)N(R0)2, SO2R0, SO2N(R0)2, or NR0SO2R0;
• wherein
• each R0 is independently selected from hydrogen, a (C1-C4)-straight or branched alkyl chain, or a 5-6 membered saturated, unsaturated, or aryl ring having 0-3 heteroatoms independently selected from N, O, or S;
• two substituents on adjacent positions of any ring may be taken together to form a 5-7 membered saturated, partially unsaturated, heterocyclic or carbocyclic ring or 5-6 membered aryl or heteroaryl ring, each ring having 0-3 heteroatoms independently selected from N, O, or S;
• Ar is a 3-8 membered saturated or unsaturated carbocyclic ring, a 5-6 membered aryl ring, a 3-7 membered heterocyclic ring having 1-3 heteroatoms independently selected from N, NR3, O, S, SO, or SO2, or a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from N, O, or S, wherein:
• Ar is optionally substituted with 1-3 J groups;
• and
• R3 is hydrogen, —(C1-C4)-straight or branched alkyl, —(C2-C4)-straight or branched alkenyl or alkynyl, -(T)y—Ar, C(O)R′, CO2R′, OR′, N(R′)2, C(O)N(R′)2, NR′C(O)R′, SO2R′, SO2N(R′)2, or NR′SO2R′;
• L is —C(O)N(R4), —N(R4)C(O), or a bond;
• wherein
• R4 is selected from hydrogen or —(C1-C3)-straight or branched alkyl;
• R1 is selected from hydrogen, halogen, OR5, or N(R5)2;
• wherein
• each R5 is independently hydrogen, —(C1-C4)-straight or branched alkyl, —(C2-C4)-straight or branched alkenyl or alkynyl, or C(O)R′;
• Q is a bond or a —(C1-C3)-straight or branched alkyl chain wherein one methylene unit of Q is optionally replaced by —NR+—, —S—, —O—, —C(S)——CO2—, —OC(O)—, —C(O)—, —C(O)C(O)—, —C(O)NR+—, —NR+C(O)—, —NR+CO2—, —SO2NR+—, —NR+SO2—, —C(O)NR+NR+—, —NR+C(O)NR+—, —OC(O)NR+—, —NR+NR+—, —NR+SO2NR+—, —S(O)—, —SO2—, —P(O)—, —PO2—, or —P(O)R+—;
• wherein R+ is independently hydrogen, —(C1-C4)-straight or branched alkyl, or —(C2-C4)-straight or branched alkenyl or alkynyl optionally substituted with 1-3 groups independently selected from halogen, oxo, R0, N(R0)2, OR0, CO2R0, NR0C(O)R0, C(O)N(R0)2, SO2R0, SO2N(R0)2, or NR0SO2R0;
• t is 0-2;
• and
• R2 is hydrogen, —(C1-C3)-straight or branched alkyl, —(C2-C4)-straight or branched alkenyl or alkynyl, halogen, NO2, CF3, CN, or Ar1;
• wherein Ar1 is a 3-7 membered monocyclic or a 6-12 membered bicyclic saturated or partially unsaturated carbocyclic ring, a 5-6 membered monocyclic or a 7-11 membered bicyclic aryl ring, a 3-7 membered monocyclic or a 6-12 membered bicyclic heterocyclic ring having 1-5 heteroatoms independently selected from N, NR3, O, S, SO, or SO2, or a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from N, O, or S;
• wherein said 5-6 membered monocyclic or 7-11 membered bicyclic aryl ring or 5-6 membered heteroaryl ring is optionally linearly fused to a second 5-6 membered aryl or heteroaryl ring having 0-3 heteroatoms independently selected from N, O, or S;
• wherein said 3-7 membered monocyclic or 6-12 membered bicyclic saturated or partially unsaturated carbocyclic ring or said 3-7 membered monocyclic or a 6-12 membered bicyclic heterocyclic ring is optionally spirocyclic or linearly fused to a 4-7 membered saturated or partially unsaturated heterocyclic or carbocyclic ring;
• wherein said 4-7 membered saturated or partially unsaturated heterocyclic or carbocyclic fused ring contains 0-3 heteroatoms independently selected from N, NR3, O, S, SO, or SO2;
• and
• wherein Ar1 is optionally substituted with 1-3 J groups.

A method of inhibiting bacterial IMPDH to treat or lessen the severity of a bacterial infection in a patient, comprising administering to said patient a therapeutically effective amount of a compound of formula I:

• or a pharmaceutically acceptable salt thereof, wherein:
• Ring A is a 5-6 membered heteroaryl ring or a 4-7 membered saturated or partially unsaturated heterocyclic ring each ring having 1-4 heteroatoms independently selected from N, NR3, O, S, SO, or SO2;
• wherein said 5-6 membered heteroaryl ring system is optionally linearly fused to a second 5-6 membered aryl or heteroaryl ring or optionally linearly fused to a 4-7 membered saturated or partially unsaturated heterocyclic or carbocyclic ring;
• wherein said 5-6 membered aryl or heteroaryl fused ring contains 0-3 heteroatoms independently selected from N, O, or S;
• wherein said 4-7 membered fused ring contains 0-3 heteroatoms independently selected from N, NR3, O, S, SO, or SO2;
• wherein said 4-7 membered saturated or partially unsaturated heterocyclic ring is optionally linearly fused to a second 5-6 membered aryl or heteroaryl ring or optionally spirocyclic bound to a 4-7 membered saturated or partially unsaturated heterocyclic or carbocyclic ring;
• wherein said 5-6 membered aryl or heteroaryl fused ring contains 0-3 heteroatoms independently selected from N, O, or S;
• wherein said 4-7 membered spirocyclic ring contains 0-3 heteroatoms independently selected from N, NR3, O, S, SO, or SO2;
• and
• wherein any of said rings is optionally substituted with up to 2 substituents independently selected from J;
• J is —(C1-C4)-straight or branched alkyl chain, —(C2-C4)-straight or branched alkenyl or alkynyl, halogen, -(T)y—Ar, -(T)y—R′, —CF3, —OCF3, oxo, —C(O)R′, —C(O)C(O)R′, —CO2R′, —OR′, —N(R′)2, —SR′, —NO2, —CN, —C(O)N(R′)2, —OC(O)N(R′)2, —NR′C(O)R′, —NR′C(O)N(R′)2, —N(OR′)R′, —C(═NOR′)R′, —SO2R′, —SO2N(R′)2, —NR′SO2R′, —P(O)R′)2, —P(O)(OR′)2, or —OP(O)(OR′)2;
• wherein
• y is 0 or 1;
• T is a (C1-C4)-straight or branched alkyl chain, wherein one methylene unit of T is optionally replaced by —O—, —C(O)—, —NH—, or —S—;
• each R′ is independently selected from hydrogen, a (C1-C4)-straight or branched alkyl chain, or a 5-6 membered saturated, unsaturated, or aryl ring having 0-3 heteroatoms independently selected from N, O, or S;
• or
• two R′ groups together with the nitrogen to which they are bound optionally form a 3-6 membered heterocyclic ring;
• and
• each R′ is substituted with 0-3 groups independently selected from halogen, oxo, R0, N(R0)2, OR0, CO2R0, NR0C(O)R0, C(O)N(R0)2, SO2R0, SO2N(R0)2, or NR0SO2R0;
• wherein
• each R0 is independently selected from hydrogen, a (C1-C4)-straight or branched alkyl chain, or a 5-6 membered saturated, unsaturated, or aryl ring having 0-3 heteroatoms independently selected from N, O, or S;
• two substituents on adjacent positions of any ring may be taken together to form a 5-7 membered saturated, partially unsaturated, heterocyclic or carbocyclic ring or 5-6 membered aryl or heteroaryl ring, each ring having 0-3 heteroatoms independently selected from N, O, or S;
• Ar is a 3-8 membered saturated or unsaturated carbocyclic ring, a 5-6 membered aryl ring, a 3-7 membered heterocyclic ring having 1-3 heteroatoms independently selected from N, NR3, O, S, SO, or SO2, or a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from N, O, or S, wherein:
• Ar is optionally substituted with 1-3 J groups;
• and
• R3 is hydrogen, —(C1-C4)-straight or branched alkyl, —(C2-C4)-straight or branched alkenyl or alkynyl, -(T)y—Ar, C(O)R′, CO2R′, OR′, N(R′)2, C(O)N(R′)2, NR′C(O)R′, SO2R′, SO2N(R′)2, or NR′SO2R′;
• L is —C(O)N(R4), —N(R4)C(O), or a bond;
• wherein
• R4 is selected from hydrogen or —(C1-C3)-straight or branched alkyl;
• R1 is selected from hydrogen, halogen, OR5, or N(R5)2;
• wherein
• each R5 is independently hydrogen, —(C1-C4)-straight or branched alkyl, —(C2-C4)-straight or branched alkenyl or alkynyl, or C(O)R′;
• Q is a bond or a —(C1-C3)-straight or branched alkyl chain wherein one methylene unit of Q is optionally replaced by —NR+—, —S—, —O—, —C(S)—, —CO2—, —OC(O)—, —C(O)—, —C(O)C(O)—, —C(O)NR+—, —NR+C(O)—, —NR+CO2, —SO2NR+—, —NR+SO2—, —C(O)NR30 NR+—, —NR30 C(O)NR30 —, —OC(O)NR+—, —NR+NR+—, —NR+SO2NR+—, —S(O)—, —SO2—, —P(O)—, —PO2—, or —P(O)R30 —;
• wherein R+ is independently hydrogen, —(C1-C4)-straight or branched alkyl, or —(C2-C4)-straight or branched alkenyl or alkynyl optionally substituted with 1-3 groups independently selected from halogen, oxo, R0, N(R0)2, OR0, CO2R0, NR0C(O)R0, C(O)N(R0)2, SO2R0, SO2N(R0)2, or NR0SO2R0;
• t is 0-2;
• and
• R2 is hydrogen, —(C1-C3)-straight or branched alkyl, —(C2-C4)-straight or branched alkenyl or alkynyl, halogen, NO2, CF3, CN, or Ar1;
• wherein Ar1 is a 3-7 membered monocyclic or a 6-12 membered bicyclic saturated or partially unsaturated carbocyclic ring, a 5-6 membered monocyclic or a 7-11 membered bicyclic aryl ring, a 3-7 membered monocyclic or a 6-12 membered bicyclic heterocyclic ring having 1-5 heteroatoms independently selected from N, NR3, O, S, SO, or SO2, or a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from N, O, or S;
• wherein said 5-6 membered monocyclic or 7-11 membered bicyclic aryl ring or 5-6 membered heteroaryl ring is optionally linearly fused to a second 5-6 membered aryl or heteroaryl ring having 0-3 heteroatoms independently selected from N, O, or S;
• wherein said 3-7 membered monocyclic or 6-12 membered bicyclic saturated or partially unsaturated carbocyclic ring or said 3-7 membered monocyclic or a 6-12 membered bicyclic heterocyclic ring is optionally spirocyclic or linearly fused to a 4-7 membered saturated or partially unsaturated heterocyclic or carbocyclic ring;
• wherein said 4-7 membered saturated or partially unsaturated heterocyclic or carbocyclic fused ring contains 0-3 heteroatoms independently selected from N, NR3, O, S, SO, or SO2;
• and
• wherein Ar1 is optionally substituted with 1-3 J groups.

A method of inhibiting bacterial IMPDH, comprising contacting bacteria with a compound of formula I:

• or a pharmaceutically acceptable salt thereof, wherein:
• Ring A is a 5-6 membered heteroaryl ring or a 4-7 membered saturated or partially unsaturated heterocyclic ring each ring having 1-4 heteroatoms independently selected from N, NR3, O, S, SO, or SO2;
• wherein said 5-6 membered heteroaryl ring system is optionally linearly fused to a second 5-6 membered aryl or heteroaryl ring or optionally linearly fused to a 4-7 membered saturated or partially unsaturated heterocyclic or carbocyclic ring;
• wherein said 5-6 membered aryl or heteroaryl fused ring contains 0-3 heteroatoms independently selected from N, O, or S;
• wherein said 4-7 membered fused ring contains 0-3 heteroatoms independently selected from N, NR3, O, S, SO, or SO2;
• wherein said 4-7 membered saturated or partially unsaturated heterocyclic ring is optionally linearly fused to a second 5-6 membered aryl or heteroaryl ring or optionally spirocyclic bound to a 4-7 membered saturated or partially unsaturated heterocyclic or carbocyclic ring;
• wherein said 5-6 membered aryl or heteroaryl fused ring contains 0-3 heteroatoms independently selected from N, O, or S;
• wherein said 4-7 membered spirocyclic ring contains 0-3 heteroatoms independently selected from N, NR3, O, S, SO, or SO2;
• and
• wherein any of said rings is optionally substituted with up to 2 substituents independently selected from J;
• J is —(C1-C4)-straight or branched alkyl chain, —(C2-C4)-straight or branched alkenyl or alkynyl, halogen, -(T)y—Ar, -(T)y—R′, —CF3, —OCF3, oxo, —C(O)R′, —C(O)C(O)R′, —CO2R′, —OR′, —N(R′)2, —SR′, —NO2, —CN, —C(O)N(R′)2, —OC(O)N(R′)2, —NR′C(O)R′, —NR′C(O)N(R′)2, —N(OR′)R′, —C(═NOR′)R′, —SO2R′, —SO2N(R′)2, —NR′SO2R′, —P(O)R′)2, —P(O)(OR′)2, or —OP(O)(OR′)2;
• wherein
• y is 0 or 1;
• T is a (C1-C4)-straight or branched alkyl chain, wherein one methylene unit of T is optionally replaced by —O—, —C(O)—, —NH—, or —S—;
• each R′ is independently selected from hydrogen, a (C1-C4)-straight or branched alkyl chain, or a 5-6 membered saturated, unsaturated, or aryl ring having 0-3 heteroatoms independently selected from N, O, or S;
• or
• two R′ groups together with the nitrogen to which they are bound optionally form a 3-6 membered heterocyclic ring;
• and
• each R′ is substituted with 0-3 groups independently selected from halogen, oxo, R0, N(R0)2, OR0, CO2R0, NR0C(O)R0, C(O)N(R0)2, SO2R0, SO2N(R0)2, or NR0SO2R0;
• wherein
• each R0 is independently selected from hydrogen, a (C1-C4)-straight or branched alkyl chain, or a 5-6 membered saturated, unsaturated, or aryl ring having 0-3 heteroatoms independently selected from N, O, or S;
• two substituents on adjacent positions of any ring may be taken together to form a 5-7 membered saturated, partially unsaturated, heterocyclic or carbocyclic ring or 5-6 membered aryl or heteroaryl ring, each ring having 0-3 heteroatoms independently selected from N, O, or S;
• Ar is a 3-8 membered saturated or unsaturated carbocyclic ring, a 5-6 membered aryl ring, a 3-7 membered heterocyclic ring having 1-3 heteroatoms independently selected from N, NR3, O, S, SO, or SO2, or a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from N, O, or S, wherein:
• Ar is optionally substituted with 1-3 J groups;
• and
• R3 is hydrogen, —(C1-C4)-straight or branched alkyl, —(C2-C4)-straight or branched alkenyl or alkynyl, -(T)y—Ar, C(O)R′, CO2R′, OR′, N(R′)2, C(O)N(R′)2, NR′C(O)R′, SO2R′, SO2N(R′)2, or NR′SO2R′;
• L is —C(O)N(R4), —N(R4)C(O), or a bond;
• wherein
• R4 is selected from hydrogen or —(C1-C3)-straight or branched alkyl;
• R1 is selected from hydrogen, halogen, OR5, or N(R5)2;
• wherein
• each R5 is independently hydrogen, —(C1-C4)-straight or branched alkyl, —(C2-C4)-straight or branched alkenyl or alkynyl, or C(O)R′;
• Q is a bond or a —(C1-C3)-straight or branched alkyl chain wherein one methylene unit of Q is optionally replaced by —NR+—, —S—, —O—, —C(S)—, —CO2—, —OC(O)—, —C(O)—, —C(O)C(O)—, —C(O)NR+—, —NR+C(O)—, —NR+CO2—, —SO2NR+—, —NR+SO2—, —C(O)NR+NR30 —, —NR+C(O)NR+—OC(O)NR+—, —NR+NR+—, —NR+SO2NR+—, —S(O)—, —SO2—, —P(O)—, —PO2—, or —P(O)R+—;
• wherein R+ is independently hydrogen, —(C1-C4)-straight or branched alkyl, or —(C2-C4)-straight or branched alkenyl or alkynyl optionally substituted with 1-3 groups independently selected from halogen, oxo, R0, N(R0)2, OR0, CO2R0, NR0C(O)R0, C(O)N(R0)2, SO2R0, SO2N(R0)2, or NR0SO2R0;
• t is 0-2;
• and
• R2 is hydrogen, —(C1-C3)-straight or branched alkyl, —(C2-C4)-straight or branched alkenyl or alkynyl, halogen, NO2, CF3, CN, or Ar1;
• wherein Ar1 is a 3-7 membered monocyclic or a 6-12 membered bicyclic saturated or partially unsaturated carbocyclic ring, a 5-6 membered monocyclic or a 7-11 membered bicyclic aryl ring, a 3-7 membered monocyclic or a 6-12 membered bicyclic heterocyclic ring having 1-5 heteroatoms independently selected from N, NR3, O, S, SO, or SO2, or a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from N, O, or S;
• wherein said 5-6 membered monocyclic or 7-11 membered bicyclic aryl ring or 5-6 membered heteroaryl ring is optionally linearly fused to a second 5-6 membered aryl or heteroaryl ring having 0-3 heteroatoms independently selected from N, O, or S;
• wherein said 3-7 membered monocyclic or 6-12 membered bicyclic saturated or partially unsaturated carbocyclic ring or said 3-7 membered monocyclic or a 6-12 membered bicyclic heterocyclic ring is optionally spirocyclic or linearly fused to a 4-7 membered saturated or partially unsaturated heterocyclic or carbocyclic ring;
• wherein said 4-7 membered saturated or partially unsaturated heterocyclic or carbocyclic fused ring contains 0-3 heteroatoms independently selected from N, NR3, O, S, SO, or SO2;
• and
• wherein Ar1 is optionally substituted with 1-3 J groups.

A pharmaceutical composition comprising a pharmaceutically acceptable carrier, adjuvant, or vehicle and a compound of formula I:

• or a pharmaceutically acceptable salt thereof, wherein:
• Ring A is a 5-6 membered heteroaryl ring or a 4-7 membered saturated or partially unsaturated heterocyclic ring each ring having 1-4 heteroatoms independently selected from N, NR3, O, S, SO, or SO2;
• wherein said 5-6 membered heteroaryl ring system is optionally linearly fused to a second 5-6 membered aryl or heteroaryl ring or optionally linearly fused to a 4-7 membered saturated or partially unsaturated heterocyclic or carbocyclic ring;
• wherein said 5-6 membered aryl or heteroaryl fused ring contains 0-3 heteroatoms independently selected from N, O, or S;
• wherein said 4-7 membered fused ring contains 0-3 heteroatoms independently selected from N, NR3, O, S, SO, or SO2;
• wherein said 4-7 membered saturated or partially unsaturated heterocyclic ring is optionally linearly fused to a second 5-6 membered aryl or heteroaryl ring or optionally spirocyclic bound to a 4-7 membered saturated or partially unsaturated heterocyclic or carbocyclic ring;
• wherein said 5-6 membered aryl or heteroaryl fused ring contains 0-3 heteroatoms independently selected from N, O, or S;
• wherein said 4-7 membered spirocyclic ring contains 0-3 heteroatoms independently selected from N, NR3, O, S, SO, or SO2;
• and
• wherein any of said rings is optionally substituted with up to 2 substituents independently selected from J;
• J is —(C1-C4)-straight or branched alkyl chain, —(C2-C4)-straight or branched alkenyl or alkynyl, halogen, -(T)y—Ar, -(T)y—R′, —CF3, —OCF3, oxo, —C(O)R′, —C(O)C(O)R′, —CO2R′, —OR′, —N(R′)2, —SR′, —NO2, —CN, —C(O)N(R′)2, —OC(O)N(R′)2, —NR′C(O)R′, —NR′C(O)N(R′)2, —N(OR′)R′, —C(═NOR′)R′, —SO2R′, —SO2N(R′)2, —NR′SO2R′, —P(O)R′)2, —P(O)(OR′)2, or —OP(O)(OR′)2;
• wherein
• y is 0 or 1;
• T is a (C1-C4)-straight or branched alkyl chain, wherein one methylene unit of T is optionally replaced by —O—, —C(O)—, —NH—, or —S—;
• each R′ is independently selected from hydrogen, a (C1-C4)-straight or branched alkyl chain, or a 5-6 membered saturated, unsaturated, or aryl ring having 0-3 heteroatoms independently selected from N, O, or S;
• or
• two R′ groups together with the nitrogen to which they are bound optionally form a 3-6 membered heterocyclic ring;
• and
• each R′ is substituted with 0-3 groups independently selected from halogen, oxo, R0, N(R0)2, OR0, CO2R0, NR0C(O)R0, C(O)N(R0)2, SO2R0, SO2N(R0)2, or NR0SO2R0;
• wherein
• each R0 is independently selected from hydrogen, a (C1-C4)-staight or branched alkyl chain, or a 5-6 membered saturated, unsaturated, or aryl ring having 0-3 heteroatoms independently selected from N, O, or S;
• two substituents on adjacent positions of any ring may be taken together to form a 5-7 membered saturated, partially unsaturated, heterocyclic or carbocyclic ring or 5-6 membered aryl or heteroaryl ring, each ring having 0-3 heteroatoms independently selected from N, O, or S;
• Ar is a 3-8 membered saturated or unsaturated carbocyclic ring, a 5-6 membered aryl ring, a 3-7 membered heterocyclic ring having 1-3 heteroatoms independently selected from N, NR3, O, S, SO, or SO2, or a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from N, O, or S, wherein:
• Ar is optionally substituted with 1-3 J groups;
• and
• R3 is hydrogen, —(C1-C4)-straight or branched alkyl, —(C2-C4)-straight or branched alkenyl or alkynyl, -(T)y—Ar, C(O)R′, CO2R′, OR′, N(R′)2, C(O)N(R′)2, NR′C(O)R′, SO2R′, SO2N(R′)2, or NR′SO2R′;
• L is —C(O)N(R4), —N(R4)C(O), or a bond;
• wherein
• R4 is selected from hydrogen or —(C1-C3)-straight or branched alkyl;
• R1 is selected from hydrogen, halogen, OR5, or N(R5)2;
• wherein
• each R5 is independently hydrogen, —(C1-C4)-straight or branched alkyl, —(C2-C4)-straight or branched alkenyl or alkynyl, or C(O)R′;
• Q is a bond or a —(C1-C3)-straight or branched alkyl chain wherein one methylene unit of Q is optionally replaced by —NR+, —S—, —O—, —C(S)—, —CO2—, —OC(O)—, —C(O)—, —C(O)C(O)—, —C(O)NR+—, —NR+C(O)—, —NR+CO2—, —SO2NR+—, —NR+SO2—, —C(O)NR+NR+—, —NR+C(O)NR+—, —OC(O)NR+—, —NR+NR+—, —NR+SO2NR+—, —S(O)—, —SO2—, —P(O)—, —PO2—, or —P(O)R+—;
• wherein R+ is independently hydrogen, —(C1-C4)-straight or branched alkyl, or —(C2-C4)-straight or branched alkenyl or alkynyl optionally substituted with 1-3 groups independently selected from halogen, oxo, R0, N(R0)2, OR0, CO2R0, NR0C(O)R0, C(O)N(R0)2, SO2R0, SO2N(R0)2, or NR0SO2R0;
• t is 0-2;
• and
• R2 is hydrogen, —(C1-C3)-straight or branched alkyl, —(C2-C4)-straight or branched alkenyl or alkynyl, halogen, NO2, CF3, CN, or Ar1;
• wherein Ar1 is a 3-7 membered monocyclic or a 6-12 membered bicyclic saturated or partially unsaturated carbocyclic ring, a 5-6 membered monocyclic or a 7-11 membered bicyclic aryl ring, a 3-7 membered monocyclic or a 6-12 membered bicyclic heterocyclic ring having 1-5 heteroatoms independently selected from N, NR3, O, S, SO, or SO2, or a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from N, O, or S;
• wherein said 5-6 membered monocyclic or 7-11 membered bicyclic aryl ring or 5-6 membered heteroaryl ring is optionally linearly fused to a second 5-6 membered aryl or heteroaryl ring having 0-3 heteroatoms independently selected from N, O, or S;
• wherein said 3-7 membered monocyclic or 6-12 membered bicyclic saturated or partially unsaturated carbocyclic ring or said 3-7 membered monocyclic or a 6-12 membered bicyclic heterocyclic ring is optionally spirocyclic or linearly fused to a 4-7 membered saturated or partially unsaturated heterocyclic or carbocyclic ring;
• wherein said 4-7 membered saturated or partially unsaturated heterocyclic or carbocyclic fused ring contains 0-3 heteroatoms independently selected from N, NR3, O, S, SO, or SO2;
• and
• wherein Ar1 is optionally substituted with 1-3 J groups.